Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer

British Journal of Cancer

Volumn 106, Issue 1, 2012, Pages 141-147

  Ferdinande, L ^a   Decaestecker, C ^b   Verset, L ^c   Mathieu, A ^c   Moles Lopez, X ^b,c   Negulescu, A M ^c   Van Maerken, T ^a   Salmon, I ^c   Cuvelier, C A ^a   Demetter, P ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

colon cancer cell lines; colorectal cancer; immunohistochemistry; indoleamine 2,3 dioxygenase 1; tumour invasion front

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84855340494     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.513     Document Type: Article

References (34)

1. Baldus SE, Mönig SP, Huxel S, Landsberg S, Hanisch FG, Engelmann K, Schneider PM, Thiele J, Hölscher AH, Dienes HP (2004) Muc1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 10: 2790-2796 (Pubitemid 38509157)
2. Beiter K, Hiendlmeyer E, Brabletz T, Hlubek F, Haynl A, Knoll C, Kirchner T, Jung A (2005) Beta-catenin regulates the expression of tenascin-c in human colorectal tumors. Oncogene 24: 8200-8204 (Pubitemid 41759818)
3. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gëbel G, Margreiter R, Königsrainer A, Fuchs D, Amberger A (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12: 1144-1151 (Pubitemid 43342502)
4. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867 (Pubitemid 36019639)
5. Cui G, Yuan A, Vonen B, Florholmen J (2009) Progressive cellular response in the lamina propria of the colorectal adenoma-carcinoma sequence. Histopathology 54: 550-560
6. Decaestecker C, Moles Lopez X, D'Haene N, Roland I, Guendouz S, Duponchelle C, Berton A, Debeir O, Salmon I (2009) Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis. Proteomics 9: 4478-4494
7. Di Carlo E, Forni G, Lollini PL, Colombo MP, Modesti A, Musiani P (2001) The intriguing role of polymorphonuclear neutrophils in anticancer reactions. Blood 97: 339-345 (Pubitemid 32060315)
8. Dumont P, Berton A, Nagy N, Sandras F, Tinton S, Demetter P, Mascart F, Allaoui A, Decaestecker C, Salmon I (2008) Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest 88: 896-906
9. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in nä?ve T cells. J Immunol 176: 6752-6761 (Pubitemid 43787857)
10. Farrar MA, Schreiber MD (1993) The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11: 571-611 (Pubitemid 23115018)
11. Ferdinande L, Demetter P, Perez-Novo C, Waeytens A, Taildeman J, Rottiers I, Rottiers P, De Vos M, Cuvelier CA (2008) Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2,3-dioxygenase. Int J Immunopathol Pharmacol 2: 289-295 (Pubitemid 351988390)
12. Gao YF, Peng RQ, Li J, Ding Y, Zhang X, Wu XJ, Pan ZZ, Wan DS, Zeng YX, Zhang XS (2009) The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med 7: 71
13. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, Ben-Ze'ev A (2005) L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168: 633-642
14. Hansen JJ, Holt L, Sartor RB (2009) Gene expression patterns in experimental colitis in IL-10 deficient mice. Inflamm Bowel Dis 15: 890-899
15. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19
16. Hiendlmeyer E, Regus S, Wasserman S, Hlubek F, Haynl A, Dimmler A, Koch C, Knoll C, Van Beest M, Reuning U, Brabletz T, Kirchner T, Jung A (2004) Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. Cancer Res 64: 1209-1214 (Pubitemid 38235582)
17. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA (2000) Indoleamine 2,3-dioxygenase production by human den dritic cells results in the inhibition of T cell proliferation. J Immunol 164: 3596-3599 (Pubitemid 30169812)
18. Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O, Kikkawa F (2009) Role of the immunosup-pressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 115: 185-192
19. Ishio T, Goto S, Tahara K, Tone S, Kawano K, Kitano S (2004) Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 19: 319-326 (Pubitemid 38338742)
20. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249
21. Kuper H, Adami HO, Trichopoulos D (2000) Infection as a major preventable cause of human cancer. J Int Med 248: 171-183
22. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, Mantovani A, Roncalli M, Malesci A (2009) CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis : a longitudinal study. Lancet Oncol 10: 877-884
23. Liu H, Liu L, Liu K, Bizargity P, Hancock WW, Visner GA (2009) Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression. J Immunol 183: 1022-1031
24. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444
25. Moffett JR, Namboodiri MA (2003) Tryptophan and the immune response. Immunol Cell Biol 81: 247-265 (Pubitemid 36904332)
26. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-318
27. Pattyn F, Robbrecht P, De Paepe A, Speleman F, Vandesompele J (2006) RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res 34(Database issue): D684-D688
28. Takikawa O, Tagawa Y, Iwakura Y, Yoshida R, Truscott RJ (1999) Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice. Adv Exp Med Biol 467: 553-557
29. Takikawa O, Yoshida R, Kido R, Hayaishi O (1986) Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem 261: 3648-3653 (Pubitemid 17200663)
30. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269-1274 (Pubitemid 37279849)
31. Waldner M, Schimanski CC, Neurath MF (2006) Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol 12: 7233-7238 (Pubitemid 44911827)
32. West NJ, Boustière C, Fischbach W, Parente F, Leicester RJ (2009) Colorectal cancer screening in Europe: differences in approach; similar barriers to overcome. Int J Colorect Dis 24: 731-740
33. Wolf AM, Wolf D, Rumpold H, Moschen AR, Kaser A, Obrist P, Fuchs D, Brandacher G, Winkler C, Geboes K, Rutgeerts P, Tilg H (2004) Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol 113: 47-55 (Pubitemid 39468267)
34. Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, Lei HY, Lai MD (2009) A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 15: 641-649